Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The company’s lead investigational therapy, AU-011, specifically targets ocular cancer cells, striving to eliminate tumors while safeguarding surrounding healthy tissue—demonstrating a commitment to precision oncology. With a robust pipeline designed to address critical unmet needs in cancer care and a highly experienced management team, Aura is strategically positioned to make significant advancements in the oncology market. Furthermore, its collaborative approach enhances innovation potential and aligns with the sector's growing demand for targeted therapies.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$7.36
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 11, 2026 | $-0.41 | $-0.48 | Miss -17.1% | $-0.48 | $0 | $0 | — | 1D Pre-3.6% | On-Day+4.4% | 1D Post-3.6% |
Q ended Mar 31, 2026 Reported May 11, 2026 | $-0.52 | $-0.50 | Beat +3.8% | — | $0 | $0 | — | 1D Pre+2.4% | On-Day-2.5% | 1D Post-3.2% |
Q ended Dec 31, 2025 Reported Mar 30, 2026 | $-0.43 | $-0.37 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-2.6% |
| On-Day-1.1% |
| 1D Post+7.9% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $-0.46 | $-0.40 | Beat +13.0% | — | $0 | $0 | — | 1D Pre-1.6% | On-Day-0.7% | 1D Post0.0% |